Hongxiu Luo, MD
Endocrinology, Diabetes & Metabolism · New Brunswick, NJNPI 1710352554
Payments from drug & device makers
Across 142 payments — averaging $29.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$991
- Novo Nordisk$531
- Boehringer Ingelheim$376
- Medtronic$347
- Corcept Therapeutics$271
- Dexcom, Inc.$235
- plus $1K from 22 others
What the payments were for
- Food & beverage$4,117100%
- Education$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 22 | $991 |
| Novo Nordisk | 29 | $531 |
| Boehringer Ingelheim | 11 | $376 |
| Medtronic(2 entities) | 7 | $347 |
| Corcept Therapeutics | 5 | $271 |
| Dexcom, Inc. | 4 | $235 |
| Lilly USA, LLC | 14 | $212 |
| Sanofi-aventis U.S. LLC | 9 | $157 |
| Insulet Corporation | 6 | $150 |
| Ambu Inc. | 1 | $118 |
| Intra-sana Laboratories | 1 | $111 |
| IBSA Pharma Inc. | 5 | $71 |
| Intuity Medical Inc | 1 | $69 |
| Bayer | 3 | $59 |
| Xeris Pharmaceuticals, Inc. | 4 | $59 |
| Radius Health, Inc. | 1 | $50 |
| Mannkind Corporation | 3 | $47 |
| Tandem Diabetes Care, Inc. | 2 | $40 |
| Amryt Pharma Holdings Ltd | 2 | $37 |
| Amgen | 2 | $30 |
| Amneal Pharmaceuticals LLC | 2 | $28 |
| AstraZeneca | 2 | $28 |
| Chiesi USA, Inc. | 1 | $25 |
| Averitas Pharma Inc. | 1 | $21 |
| Exact Sciences | 1 | $21 |
| AbbVie | 1 | $18 |
| Cequr Corporation | 1 | $17 |
| Pfizer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FREESTYLE LIBRE 3$748
- Korlym$228
- DEXCOM G6 TRANSMITTER$175
- MINIMED 780G$155
- OFEV$125
- Ozempic$120
- Reltone 200 Mg$111
- GLYCATE$111
- Reltone 400 Mg$111
How this compares
$4,133 in reported general payments places this provider in the 65th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
See all endocrinology, diabetes & metabolism providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 267 | $406,898 |
| TrulicityDulaglutide | 111 | $181,635 |
| JardianceEmpagliflozin | 110 | $129,143 |
| FarxigaDapagliflozin Propanediol | 54 | $59,657 |
| JanuviaSitagliptin Phosphate | 32 | $32,028 |
| TradjentaLinagliptin | 31 | $28,745 |
| Tresiba Flextouch U-200Insulin Degludec | 35 | $27,416 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 45 | $27,248 |
| Humalog Kwikpen U-100Insulin Lispro | 91 | $22,748 |
| Bydureon BciseExenatide Microspheres | 17 | $21,307 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 44 | $20,281 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $19,521 |
| MounjaroTirzepatide | 12 | $18,233 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 168 | $16,928 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 113 | $16,286 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $531 | $406,898267 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $212 | $202,261135 claims |
| Boehringer IngelheimJardiance, Tradjenta | $376 | $157,888141 claims |
| AstraZenecaFarxiga | $28 | $59,65754 claims |
| AbbVieSynthroid | $18 | $3,21943 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $28 | $2,296238 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
Other endocrinology, diabetes & metabolism in New Brunswick
- Joanne WaldstreicherNew Brunswick$441K
- Sara LubitzNew Brunswick$161K
- Peter SteinNew Brunswick$40K
- Manu ChakravarthyNew Brunswick$16K
- Arthur SantoraNew Brunswick$15K
- Barry GertzRahway$903K
- Nawras MakhsidaRandolph$882K
- Marc SandbergFlemington$567K
- Gregory BaroneCherry Hill$433K
- Taher ModarressiPennington$414K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.